[New triple therapy for Helicobacter pylori infection in Japan].
In Japan, a phase 3 trial of 1-week triple therapy with lansoprazole(L), amoxicillin(A), and clarithromycin(C) was finished in March, 2000. Patients were randomized into three groups: L 30 mg bid and placebos, and L 30 mg bid, A 750 mg bid and C 200 mg bid or 400 mg bid. Eradication rates were high in group LAC200(88-91%) and group LAC400 (84-89%). Next, a phase 3 trial of 1-week triple therapy with omeplazole (O), A and C was finished in 2001. Eradication rates were 78.8% in the group of O 20 mg, A 750 mg and C 400 mg bid, and 83.0% in the group of O 20 mg, A 1,000 mg, and C 500 mg bid.
Satoh
Kiichi
K
Division of Gastroenterology, Department of Internal Medicine, Jichi Medical School.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000008:administration & dosage*; D017291:Clarithromycin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000008:administration & dosage* / Q000031:analogs & derivatives
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole